Division of Surgical Oncology, Wake Forest Baptist Health, USA.
Department of Biostatistics and Data Sciences, Wake Forest School of Medicine, USA.
HPB (Oxford). 2020 Sep;22(9):1265-1270. doi: 10.1016/j.hpb.2019.12.003. Epub 2020 Jan 17.
Recent reports indicate improved survival in patients undergoing surgical treatment for colorectal liver metastases (CRLM) with hepatic arterial infusion (HAI) pump chemotherapy compared to surgery alone.
Patients who underwent resection and/or ablation of CRLM between 1996 and 2016 were included from a single-institution prospectively maintained database. Proportional hazards regression analysis was performed to determine predictors of overall survival (OS) and 3:1 propensity score analysis (PSA).
Of 349 patients included, 36 had HAI pumps placed (HAI group) and 313 did not (no-HAI group). There was no difference in primary tumor grade (p = 0.24), ECOG status (p = 0.44), tumor number (p = 0.1), tumor size (p = 0.56), margin status (p = 0.76) between the two groups. Median overall survival was 44.7months vs 37.1months for the HAI versus no-HAI group (p = 0.01). Cox proportional hazards regression analysis demonstrated positive margin status (HR:2.47,p < 0.0001), HAI therapy (HR:0.56,p = 0.02), preoperative chemotherapy (HR:0.69,p = 0.02) and tumor diameter (HR:1.07,p = 0.005) as predictors of OS. In 3:1 PSA, 32 HAI subjects were matched with 87 non-HAI subjects balancing all covariates. Median OS was 42.4 months versus 35.6 months for the HAI versus no-HAI group (p = 0.03).
Surgical treatment of CRLM combined with HAI chemotherapy is associated with improved OS compared to surgery alone. Further study of this treatment approach is indicated.
最近的报告表明,与单独手术相比,接受结直肠肝转移(CRLM)手术治疗并接受肝动脉灌注(HAI)泵化疗的患者的生存时间有所改善。
从一个单中心前瞻性维护的数据库中纳入了 1996 年至 2016 年间接受 CRLM 切除术和/或消融术的患者。采用比例风险回归分析确定总生存(OS)和 3:1 倾向评分分析(PSA)的预测因素。
在 349 例患者中,有 36 例放置了 HAI 泵(HAI 组),313 例未放置(无 HAI 组)。两组之间的原发肿瘤分级(p=0.24)、ECOG 状态(p=0.44)、肿瘤数量(p=0.1)、肿瘤大小(p=0.56)和切缘状态(p=0.76)无差异。HAI 组与无 HAI 组的中位总生存时间分别为 44.7 个月和 37.1 个月(p=0.01)。Cox 比例风险回归分析显示,阳性切缘状态(HR:2.47,p<0.0001)、HAI 治疗(HR:0.56,p=0.02)、术前化疗(HR:0.69,p=0.02)和肿瘤直径(HR:1.07,p=0.005)是 OS 的预测因素。在 3:1 PSA 中,32 例 HAI 患者与 87 例非 HAI 患者进行了匹配,平衡了所有协变量。HAI 组和无 HAI 组的中位 OS 分别为 42.4 个月和 35.6 个月(p=0.03)。
与单独手术相比,CRLM 的手术治疗联合 HAI 化疗可改善 OS。需要进一步研究这种治疗方法。